HIGH-DOSE BIWEEKLY INTRAPERITONEAL CISPLATIN - AN EFFECTIVE WAY TO INCREASE CISPLATIN DOSE INTENSITY

被引:5
作者
BONETTI, A
HOWELL, SB
MCCLAY, E
KIRMANI, S
GOEL, R
PLAXE, S
BRALY, P
KIM, S
机构
[1] UNIV CALIF SAN DIEGO,DEPT REPROD MED,LA JOLLA,CA 92093
[2] UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093
关键词
D O I
10.1006/gyno.1993.1133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The amount of cisplatin (DDP) delivered per unit time (dose intensity, expressed in mg/m2/week) may be an important factor in determining the clinical outcome in tumors such as ovarian carcinoma. In this neoplasm, intraperitoneal chemotherapy is an effective form of treatment. In this trial we have explored the tactic of shortening the cycle interval as a way to increase the dose intensity of ip DDP. Sixteen patients with a variety of solid tumors received a total of 77 cycles of DDP 180 mg/m2 instilled ip concurrent with iv sodium thiosulfate at the dose of 4 g/m2 as loading dose, followed by 12 g/m2 over 6 hr. Each cycle was repeated every 2 weeks. The number of cycles delayed for 3 or more days was 28 (36%). The mean DDP dose intensity received by these patients was 77% of the planned dose or 69 mg/m2/week (confidence interval 95%, 60.5-77.5). The treatment was generally well tolerated: myelotoxicity was mild, only 1 patient had an increase in serum creatinine to >2 mg/dl. Five patients (31%) developed symptoms of peripheral neuropathy. All patients were evaluable for response. The overall response rate (complete plus partial) in these heavily pretreated patients was 19%. When DDP is given in high doses by the ip route concurrently with systemic sodium thiosulfate, the dosing interval can be reduced to every 2 weeks permitting a marked increase in DDP dose intensity. © 1993 Academic Press, Inc.
引用
收藏
页码:318 / 324
页数:7
相关论文
共 33 条
[1]  
BLUMENREICH MS, 1985, CANCER, V55, P1118, DOI 10.1002/1097-0142(19850301)55:5<1118::AID-CNCR2820550529>3.0.CO
[2]  
2-5
[3]  
BRUKNER HW, 1981, GYNECOL ONCOL, V12, P64
[4]   HIGH-DOSE CISPLATIN IN HYPERTONIC SALINE - REDUCED TOXICITY OF A MODIFIED DOSE SCHEDULE AND CORRELATION WITH PLASMA PHARMACOKINETICS - A NORTHERN CALIFORNIA ONCOLOGY GROUP PILOT-STUDY IN NON-SMALL-CELL LUNG-CANCER [J].
GANDARA, DR ;
DEGREGORIO, MW ;
WOLD, H ;
WILBUR, BJ ;
KOHLER, M ;
LAWRENCE, HJ ;
DEISSEROTH, AB ;
GEORGE, CB .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (12) :1787-1793
[5]   EFFECT OF SODIUM THIOSULFATE ON THE PHARMACOKINETICS AND TOXICITY OF CISPLATIN [J].
GOEL, R ;
CLEARY, SM ;
HORTON, C ;
KIRMANI, S ;
ABRAMSON, I ;
KELLY, C ;
HOWELL, SB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (20) :1552-1560
[6]   SUCCESSFUL TREATMENT OF RESISTANT GERMINAL NEOPLASMS WITH VP-16 AND CISPLATIN - RESULTS OF A SOUTHEASTERN CANCER STUDY-GROUP TRIAL [J].
HAINSWORTH, JD ;
WILLIAMS, SD ;
EINHORN, LH ;
BIRCH, R ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (05) :666-671
[7]  
HOWELL SB, 1991, SEMIN ONCOL, V18, P5
[8]  
HOWELL SB, 1982, ANN INTERN MED, V97, P848
[9]   THE IMPORTANCE OF DOSE INTENSITY IN CHEMOTHERAPY OF METASTATIC BREAST-CANCER [J].
HRYNIUK, W ;
BUSH, H .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1281-1288
[10]   RANDOMIZED STUDY OF 2 DOSES OF CISPLATIN WITH CYCLOPHOSPHAMIDE IN EPITHELIAL OVARIAN-CANCER [J].
KAYE, SB ;
LEWIS, CR ;
PAUL, J ;
DUNCAN, ID ;
GORDON, HK ;
KITCHENER, HC ;
CRUICKSHANK, DJ ;
ATKINSON, RJ ;
SOUKOP, M ;
RANKIN, EM ;
CASSIDY, J ;
DAVIS, JA ;
REED, NS ;
CRAWFORD, SM ;
MACLEAN, A ;
SWAPP, GA ;
SARKAR, TK ;
KENNEDY, JH ;
SYMONDS, RP .
LANCET, 1992, 340 (8815) :329-333